🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Acadia Pharmaceuticals appoints new CEO, shares jump 10%

Published 23/09/2024, 21:24
© Reuters.
ACAD
-


On Monday, shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) fell 2.5% following the announcement that Catherine Owen Adams has taken over from Steve Davis as Chief Executive Officer (CEO) and has also joined the company's Board of Directors.

The transition marks a significant leadership change for the biopharmaceutical firm, which is nearing $1 billion in sales and has a robust pipeline of medicines in development.

Stephen Biggar, Chair of the Board of Directors, expressed confidence in Adams' ability to lead Acadia into a new growth phase, highlighting her record of driving growth and innovation within the pharmaceutical industry.

Biggar commended Adams for her strategic vision and expertise, particularly in relation to improving patient outcomes. He also extended gratitude to the outgoing CEO, Steve Davis, for his exceptional leadership and contributions to the company, including the approval and commercialization of NUPLAZID and the development and launch of DAYBUE.

Adams, who expressed her enthusiasm about joining Acadia, brings a wealth of experience to her new role. Her previous position as Senior Vice President and General Manager, U.S., at Bristol Myers (NYSE:BMY) Squibb (BMS), saw her leading a $20 billion commercial business and overseeing significant product launches.

Before her role at BMS, Adams had a 25-year tenure at Johnson & Johnson (NYSE:JNJ), where she held various leadership positions and began her career in R&D and manufacturing at AstraZeneca (NASDAQ:AZN).

The new CEO's appointment has been met with positive remarks from her predecessor, Steve Davis, who praised Adams' commercial and global expertise as perfectly aligned with Acadia's mission. Davis expressed his excitement for the company's future and its commitment to patient groups that have previously lacked approved drugs.

Adams' extensive background includes leading commercial operations across major markets at BMS, where she was responsible for 6,000 employees and the successful launch of nine new products in various therapeutic areas.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.